Please select the option that best describes you:
Topics:
Lung Cancer • Radiation Oncology • Thoracic Malignancies • Non-small cell lung cancer • EGFR+
Is PORT recommended for incidentally found N2+ NSCLC after lobectomy for oligoprogressive metastatic NSCLC?
Does EGFR+ status influence your decision? What is the significance of this finding and its potential for progression? Is it simply occult disease controlled on EGFR therapy?
Answer from: Radiation Oncologist at Academic Institution
I would say it should probably be used very selectively in this population.
We routinely use PORT for stage 3 patients who have incidentally discovered N2 nodes, but I try to keep in mind that that evidence supporting its use is not strong, even in the curative setting. There's a consi...
Sign in or Register to read more